Parkinson's disease-associated ATP13A2/PARK9 functions as a lysosomal H,K-ATPase.

Mutations in the human ATP13A2 (PARK9), a lysosomal ATPase, cause Kufor-Rakeb Syndrome, an early-onset form of Parkinson's disease (PD). Here, we demonstrate that ATP13A2 functions as a lysosomal H,K-ATPase. The K-dependent ATPase activity and the lysosomal K-transport activity of ATP13A2 are inhibited by an inhibitor of sarco/endoplasmic reticulum Ca-ATPase, thapsigargin, and K-competitive inhibitors of gastric H,K-ATPase, such as vonoprazan and SCH28080.

Re-evaluation of the prognosis of alpha-fetoprotein-producing gastric cancer from a single center: a case series study.

Background: Alpha-fetoprotein (AFP)-producing gastric cancer (AFPGC) is reported to have biologically aggressive features and poor prognosis. A relatively large number of patients with AFPGC have achieved a long-term prognosis after surgery in our institution. This study aimed to clarify the clinical features of and re-evaluate the long-term outcomes of AFPGC.

Understanding Micro and Atomic Structures of Secondary Phases in Cu-Doped SnTe.

Highly efficient thermoelectric materials require, including point defects within the host matrix, secondary phases generating positive effects on lowering lattice thermal conductivity (κ ). Amongst effective dopants for a functional thermoelectric material, SnTe, Cu doping realizes the ultra-low κ approaching the SnTe amorphous limit. Such effective κ reduction is first attributed to strong phonon scattering by substitutional Cu atoms at Sn sites and interstitial defects in the host SnTe.

Clinical significance of initial treatment for peritoneal lavage cytology-positive gastric cancer: outcomes according to treatment strategy.

Background: Although patients with positive lavage cytology (CY1) are classified as having stage IV disease, long-term survival without other unresectable factors (P0CY1) has been reported. Conversion gastrectomy in patients with a change in cytology status after induction chemotherapy might improve survival, but appropriate treatment remains controversial. Here, we reviewed our experience in treating CY1 gastric cancer to evaluate the best treatment strategy.